On December 11, 2023, Beijing Minhai Biotechnology Co., Ltd., a wholly owned subsidiary of Kangtai Biological, signed an Agreement on Licensing and Technology Transfer for the 13-valent pneumococcal polysaccharide conjugate vaccine with the Egyptian vaccine company Gennvax Egypt. The two parties have entered into a commercial cooperation agreement to grant licensing and transfer technology for Minhai Biotechnology’s independently developed and manufactured world’s first dual‑carrier 13-valent pneumococcal polysaccharide conjugate vaccine, jointly advancing the approval and market launch of the finished vaccine in Egypt, as well as local bulk‑filling operations.

The signing ceremony was held with great solemnity at the Beijing Minhai International New‑Type Vaccine Internationalization Industrial Base. Zheng Haifa, General Manager of Minhai, and Dr. Nibal Dahaba, General Manager of Gennvax, signed the “License Agreement for the 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine and Technology Transfer Agreement” on behalf of Beijing Minhai Biotechnology Co., Ltd. and the Egyptian vaccine company Gennvax Egypt.

Egyptian Ambassador to China, Mr. Assem Hanafi; Minister Plenipotentiary of the Egyptian Economic and Commercial Office in China, Mr. Ahamed Zaki; Commercial Counselor of Egypt, Mr. Amr Mohie eldin; representative of the Egyptian Ministry of Health, Dr. Sherif Shawki Ali; Li Quanle, Deputy Secretary-General of the Chinese Society of Preventive Medicine; Dong Qiang, Second-Level Inspector of the Beijing Municipal Science & Technology Commission and the Zhongguancun Science Park Administrative Committee; Gao Yan, Deputy Director of the Biomedical Base in Daxing District, Beijing; Bai Yumei, Deputy General Manager of the Management Committee of the Biomedical Base in Daxing District, Beijing; Gao Qian, Senior Executive at the Beijing Pharmaceutical and Health Technology Center; Ms. Sherine Shawky Azer, Head of Public Affairs and Business at the Egyptian vaccine company Gennvax Egypt; Project Leader Dr. Richard Van Duyse; Consultant Dr. Nabil EL Beblawy; Miao Xiang, President of Kangtai Group; Liu Jiankai, Deputy General Manager of Minhai; Nie Xiaoqi, Deputy General Manager of Quality; Zheng Jingshan, Assistant to the President and Head of Pharmacovigilance; Tong Wei, Deputy Director of Production; Zhang Qian, General Manager of the International Business Division—along with other distinguished guests—jointly witnessed the signing ceremony.

Miao Xiang, President of Kangtai Biological, Dr. Nibal Dahaba, General Manager of Gennvax, and other representatives from both companies attended the ceremony and delivered remarks.

     Pneumococcal disease It is one of the world’s most serious public health problems, causing diseases such as pneumonia, meningitis, and otitis media, with particularly severe consequences for children. Therefore, the World Health Organization ( WHO ) Classifies pneumococcal disease as a disease for which vaccination is of extremely high priority. Currently, more than… worldwide have already… 85% The country will Pneumococcal polysaccharide conjugate vaccine ( PCV ) Include it in their national immunization program.

According to statistics from the United Nations Population Fund, 2023 The total population of Egypt reached 1.127 billion, ranking first in the world in terms of population 14 Position, the number of newborns is approximately 260 Ten thousand, the birth rate is 23.635‰ . The localization of vaccine manufacturing is in Egypt 2030 An important component of the annual vision, the Egyptian government is currently planning to… PCV13 Incorporate it into the immunization program and encourage domestic vaccine manufacturers to produce vaccines locally.

At the signing ceremony, Miao Xiang, President of Kangtai Group, stated: “Vaccines are globally recognized as the most cost-effective, most effective, and safest means of preventing and controlling infectious diseases. Kangtai Biological’s dual-vector…” 13 Pneumococcal vaccine Clinical trials have demonstrated that its immunogenicity and safety are both outstanding, placing it at the forefront worldwide. It is hoped that, through this collaboration, both parties will jointly enhance the vaccine’s accessibility and affordability across the African Union region, with Egypt as its focal point. ”。

Zhang Qian, General Manager of the International Business Division of Kangtai Group, outlined the group’s and Minhai Biologics’ strengths and progress in areas such as marketed products, R&D pipelines, production capacity, and overseas expansion. He also stated that the company has consistently deepened its international collaborations in the vaccine field, striving to ensure that… “ Chinese vaccine ” Entering the international market, building “ Chinese vaccines, manufactured in multiple countries, serving the world. ” The pattern.

Gennvax General Manager Dr. Nibal Dahaba It introduced the company’s state-of-the-art production base and stated that, as Egypt’s first domestically established vaccine manufacturer, it aims to serve as a bridge for China–Africa vaccine cooperation, helping Egypt achieve… 2030 the vision for local vaccine production and actively promote it Gavi, the Vaccine Alliance ( GAVI ) Fulfill its commitment to support the localization of vaccine production in Africa.

Gennvax Co-founder & General Manager Dr. Nibal Dahaba Address

Egyptian Ambassador to China Mr. Assem Hanafy He extended his congratulations on the signing, noting that China and Egypt have forged a close partnership in the field of public health, lighting a beacon of cooperation, mutual benefit, and shared progress. In today’s interconnected world, this collaboration underscores the two countries’ commitment and capacity to advance the health and well-being of their peoples.

Li Quanle, Deputy Secretary-General of the Chinese Society of Preventive Medicine, stated that this cooperation agreement marks a milestone in the international expansion of Chinese vaccine companies, with Minhai Biologics as a leading example, elevating China–Egypt cooperation in the vaccine sector to a new level. He expressed the hope that Minhai Biologics will proactively expand both domestic and international markets, drive high-quality development in the pharmaceutical and health industries, continue to serve as a flagship enterprise in the biopharmaceutical field, remain at the forefront of science‑based pandemic prevention, strengthen research and innovation, develop robust, high‑quality products, and deliver tangible benefits to the broader public.

Representative of the Egyptian Ministry of Health Dr. Sherif Shawki Ali It was stated that, as Africa’s gateway, Egypt can play a pivotal role in fostering ties with other countries in the region. Through international cooperation, African vaccines could achieve localized production, laying a solid foundation for ensuring self-sufficiency in basic immunization supplies across the region.

Kangtai Group has always upheld the mission of “creating better vaccines to benefit human health,” using Chinese vaccines to build a robust immunization barrier for tens of millions of children. Looking ahead, Kangtai will collaborate with more partners to help Belt and Road countries establish sustainable vaccine research, development, and manufacturing systems, bridge the “immunization gap,” and promote the health of people worldwide.

(Group photo of guests at the signing ceremony)